Melanoma clinical trials in Texas
79 studies for Melanoma are looking for participants at sites in Texas.
Cities in Texas
- Houston61 studies
- Dallas21 studies
- San Antonio16 studies
- Austin11 studies
- Killeen3 studies
- Fort Worth3 studies
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Call for Information (Investigational Site 0054), Dallas
RecruitingPhase 1/2
6 Months – 17 Years · All sexes · Updated Nov 13, 2026 · NCT02332668High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
- M D Anderson Cancer Center, Houston
Recruiting
Ages 19 and older · All sexes · Updated Nov 12, 2026 · NCT05053555Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
- M D Anderson Cancer Center, Houston
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT04751396BostonGene and Exigent Genomic INsight Study
- Oncology Consultants, Houston
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06272864A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- NEXT Austin, Austin
- START Center for Clinical Research, Fort Worth
- University of Texas MD Anderson Cancer Center, Houston
- and 2 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06270706Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
- M D Anderson Cancer Center, Houston
Recruiting
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT03941756Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 12 to 50 · All sexes · Updated Nov 10, 2026 · NCT03093909A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- Texas Oncology - Austin Midtown, Midtown Medical Center I, Austin
- Texas Oncology - Austin Central, Central Austin Cancer Center, Austin
- Texas Oncology - South Austin, South Austin Cancer Center, Austin
- and 12 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT06246916Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- The University of Texas Health Science Center at Tyler, Tyler
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT04198766Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- The Don and Sybil Harrington Cancer Center, Amarillo
- UT MD Anderson Cancer Center, Houston
- Audie L Murphy VA Hospital, San Antonio
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069SI-B036-ST-101 in Advanced/Metastatic Solid Tumors
- Mary Crowley Cancer Research, Dallas
- MD Anderson, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07857616A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07492680Safety and Efficacy of OBX-115 in Advanced Solid Tumors
- M.D. Anderson Cancer Center (Melanoma/NSCLC), Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06060613Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases
- The University of Texas M. D. Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07444606A Study of BI 3810944 in Patients With Advanced Cancer
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT07224425DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA13-0, Anderson
- USA12-0, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06953089A Study of MGC026 in Participants With Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT06242470A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Texas Oncology - West Texas, Amarillo
- Texas Oncology, P.A., Dallas
- Texas Oncology Gulf Coast, Pearland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06330064A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06172478Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
- Texas Oncology, Austin
- Texas Oncology - Dallas SCRI, Dallas
- University of Texas-MD Anderson, Houston
- and 2 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT07287917Intratumoral N17350 in Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT07339176A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 135, Austin
- Research Site 120, Dallas
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT05914116A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
- START San Antonio, San Antonio
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06880549A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, San Antonio
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT07749586A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics (START), LLC, San Antonio
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 9, 2026 · NCT07070232A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Research Site, Houston
- Research Site, San Antonio
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 8, 2026 · NCT07115043Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic
- M D Anderson Cancer Center, Houston
RecruitingObservational study
All ages · All sexes · Updated Oct 7, 2026 · NCT04474301Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
- MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 6, 2026 · NCT06545682IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
- M D Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 6, 2026 · NCT05039801Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)
- MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT06660420Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
- MD Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06548789DESTINY-PANTUMOUR04
- Research Site, Dallas
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Baylor, Scott and White Research Institute, Dallas
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379Pan-tumor MRD Study
- Onocology Consultants P.A. (Oncology Consultants [OC Houston]), Houston
- Community Clinical Trials, Kingwood
- Christus St. Michael's, Texarkana
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06605404A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
- Dell Children's Medical Center of Central Texas, Austin
- UT MD Anderson Cancer Center, Houston
RecruitingPhase 2
Up to age 25 · All sexes · Updated Sep 24, 2026 · NCT07621614Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Texas Oncology (Balcones) - SCRI, Austin
- MD Anderson Cancer Center, Houston
- START South Texas Accelerated Research Therapeutics, San Antonio
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT05267626Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
- M D Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT04038619ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- UT Southwestern Medical Center, Dallas
- DHR Health Advance Care Center, Edinburg
- The Center for Cancer and Blood Disorders, Forth Worth
- and 1 more
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT05059444DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
- UT Southwestern, Dallas
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT07288112A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
- MD Anderson, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT04913285From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.